Photocure Q2 FY26 adjusted EBITDA rises 0.74% to NOK 27.2 million; revenue increases 5.09% to NOK 142.5 million

• Photocure Q2 2026 revenue rose 5.1% to NOK 142.5 million, while IFRS EBITDA swung to a loss of NOK 2 million.
• IFRS EBIT loss widened to NOK 9.4 million; adjusted EBITDA increased 0.7% to NOK 27.2 million.
• Cash and cash equivalents totaled NOK 162.4 million at quarter-end; U.S. active accounts climbed 20% to 436.
• Acquired Vesica Health, adding AssureMDx; expects initial revenue in 2027 with reimbursement anticipated by mid-2028.
• Outlook raised for 2026 product revenue growth to 8%-11% on a constant-currency basis, while guiding to adjusted EBITDA margin expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.